ArriVent BioPharma, Inc. Common Stock
AVBPNASDAQHealthcare● Active
$30.39
+$0.04(+0.14%)
Market Cap$1.4B
P/E Ratio—
52W High$32.14
52W Low$16.1
ArriVent BioPharma, Inc. Common Stock (AVBP) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
AVBP · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 11, 2026EPS Actual
-$0.96
Est. -$0.88 · -9.1%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 11, 2026
After Market Close
▼ Miss EPS
AVBP reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 10, 2026 | -$0.98 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 11, 2026 | -$0.88 | -$0.96 | -9.1% | — | — | — |
| ▲ Q1 FY2026 | Mar 5, 2026 | -$0.87 | -$0.78 | +10.3% | — | — | — |
| ▼ Q4 FY2025 | Nov 10, 2025 | -$0.78 | -$0.83 | -6.4% | — | — | — |
| ▼ Q3 FY2025 | Aug 11, 2025 | -$0.70 | -$0.90 | -28.6% | — | — | — |
| ▼ Q2 FY2025 | May 12, 2025 | -$0.66 | -$1.90 | -187.9% | — | — | — |
| ▲ Q1 FY2025 | Mar 3, 2025 | -$0.78 | -$0.60 | +23.1% | — | — | — |
| ▲ Q4 FY2024 | Nov 14, 2024 | -$0.82 | -$0.61 | +25.6% | — | — | — |
Q3 FY2026
Aug 10, 2026
EPS Actual
—
EPS Est.
-$0.98
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 11, 2026Miss
EPS Actual
-$0.96
EPS Est.
-$0.88
EPS Surpr.
-9.1%
Revenue
—
Q1 FY2026
Mar 5, 2026Beat
EPS Actual
-$0.78
EPS Est.
-$0.87
EPS Surpr.
+10.3%
Revenue
—
Q4 FY2025
Nov 10, 2025Miss
EPS Actual
-$0.83
EPS Est.
-$0.78
EPS Surpr.
-6.4%
Revenue
—
Q3 FY2025
Aug 11, 2025Miss
EPS Actual
-$0.90
EPS Est.
-$0.70
EPS Surpr.
-28.6%
Revenue
—
Q2 FY2025
May 12, 2025Miss
EPS Actual
-$1.90
EPS Est.
-$0.66
EPS Surpr.
-187.9%
Revenue
—
Q1 FY2025
Mar 3, 2025Beat
EPS Actual
-$0.60
EPS Est.
-$0.78
EPS Surpr.
+23.1%
Revenue
—
Q4 FY2024
Nov 14, 2024Beat
EPS Actual
-$0.61
EPS Est.
-$0.82
EPS Surpr.
+25.6%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.84 | $-0.84 | $-0.84 | 1 |
| Q3 FY2027 | $-1.03 | $-1.03 | $-1.03 | 1 |
| Q2 FY2027 | $-1.06 | $-1.06 | $-1.06 | 1 |
| Q1 FY2027 | $-1.02 | $-1.02 | $-1.02 | 1 |
| Q4 FY2026 | $-1.07 | $-1.07 | $-1.07 | 1 |
| Q3 FY2026 | $-1.04 | $-1.01 | $-0.97 | 5 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 11, 2026 | -9.1% | $29.50 | $29.02 | -1.63% |
| ▲ Q1 FY2026 | Mar 5, 2026 | +10.3% | $26.56 | $25.25 | -4.93% |
| ▼ Q4 FY2025 | Nov 10, 2025 | -6.4% | $18.05 | $18.60 | +3.05% |
| ▼ Q3 FY2025 | Aug 11, 2025 | -28.6% | $17.99 | $17.39 | -3.34% |
| ▼ Q2 FY2025 | May 12, 2025 | -187.9% | $20.15 | $19.99 | -0.79% |
| ▲ Q1 FY2025 | Mar 3, 2025 | +23.1% | $23.61 | $22.03 | -6.69% |
| ▲ Q4 FY2024 | Nov 14, 2024 | +25.6% | $31.86 | $28.08 | -11.86% |
| ▲ Q3 FY2024 | Aug 14, 2024 | +0.0% | $23.11 | $23.95 | +3.63% |
Q2 FY2026-1.63%
Report Date
May 11, 2026
EPS Beat/Miss
-9.1%
Price Before
$29.50
Price After
$29.02
Q1 FY2026-4.93%
Report Date
Mar 5, 2026
EPS Beat/Miss
+10.3%
Price Before
$26.56
Price After
$25.25
Q4 FY2025+3.05%
Report Date
Nov 10, 2025
EPS Beat/Miss
-6.4%
Price Before
$18.05
Price After
$18.60
Q3 FY2025-3.34%
Report Date
Aug 11, 2025
EPS Beat/Miss
-28.6%
Price Before
$17.99
Price After
$17.39
Q2 FY2025-0.79%
Report Date
May 12, 2025
EPS Beat/Miss
-187.9%
Price Before
$20.15
Price After
$19.99
Q1 FY2025-6.69%
Report Date
Mar 3, 2025
EPS Beat/Miss
+23.1%
Price Before
$23.61
Price After
$22.03
Q4 FY2024-11.86%
Report Date
Nov 14, 2024
EPS Beat/Miss
+25.6%
Price Before
$31.86
Price After
$28.08
Q3 FY2024+3.63%
Report Date
Aug 14, 2024
EPS Beat/Miss
+0.0%
Price Before
$23.11
Price After
$23.95
Avg Beat Reaction-4.96%
Avg Miss Reaction-0.68%
Beat Rate4 / 8 quarters
Largest Move-11.86% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: AVBP ends December
ArriVent BioPharma, Inc. Common Stock (AVBP) most recently reported earnings on May 11, 2026 for Q2 FY2026, posting EPS of $-0.96 — missing the analyst consensus of $-0.88 by -9.1%. The next AVBP earnings date is expected around September 1, 2026.
Each quarter, investors track AVBP earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. AVBP revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
AVBP's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
AVBP earnings · 5 questionsArriVent BioPharma, Inc. Common Stock's next earnings report is expected around September 1, 2026. AVBP typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; AVBP historically reports after market close (AMC).
AVBP earnings datewhen is AVBP earningsAVBP next earnings datewhen does AVBP report earningsAVBP earnings calendar
▸ Source: FMP · ArriVent BioPharma, Inc. Common Stock SEC filings · US GAAP · ArriVent BioPharma, Inc. Common Stock SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026